There are currently 1519 clinical trials in Baltimore, Maryland looking for participants to engage in research studies. Trials are conducted at various facilities, including Johns Hopkins University, Johns Hopkins Hospital, University of Maryland and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
NCT04753879
Recruiting
The purpose of this study is to evaluate the safety and clinical activity of maintenance olaparib and pembrolizumab following multi-agent, low dose chemotherapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with untreated metastatic pancreatic ductal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Feasibility Study on Radiofrequency-Based Selective Electrothermolysis to Investigate Its Effects on Human Skin
NCT05066113
Recruiting
This research is being done to assess the effect of radiofrequency (RF)-based treatment on skin and skin conditions.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
06/10/2025
Locations: Johns Hopkins School of Medicine, Baltimore, Maryland
Conditions: Hidradenitis Suppurativa, Healthy Volunteers
Register for Updates
Thoraflex Hybrid and Relay Extension Post-Approval Study
NCT05639400
Recruiting
The goal of this observational study is to evaluate the Thoraflex Hybrid device alone and in combination with the RelayPro NBS stent-graft in the treatment of aortic disease affecting the aortic arch and descending aorta with or without involvement of the ascending aorta. Patients who undergo treatment with the Thoraflex Hybrid device with or without extension with a RelayPro NBS stent-graft will be eligible for enrolment and study activities and follow-up regime will follow standard care at ea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm, Thoracic Aortic Dissection
Register for Updates
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
NCT03845205
Recruiting
Given the severe consequences of alcohol relapse following liver transplantation for alcoholic hepatitis (AH-LT), it is critical to accurately identify alcohol use and implement alcohol interventions early in the post-transplant period to optimize patient outcomes. The proposed randomized clinical trial will examine the implementation and effects of integrated, person- and computer-delivered alcohol treatment compared to standard care on alcohol use (assessed by self-report and biomarker), mood,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Johns Hopkins University School of Medicine, Baltimore, Maryland
Conditions: Alcohol Use Disorder, Alcoholic Hepatitis
Register for Updates
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
NCT04378790
Recruiting
A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to \<13 years of age.
Gender:
ALL
Ages:
Between 3 years and 13 years
Trial Updated:
06/09/2025
Locations: Wilmer Eye Institute, Baltimore, Maryland
Conditions: Amblyopia
Register for Updates
Bevacizumab Treatment For Type 1 ROP
NCT04634578
Recruiting
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Gender:
ALL
Ages:
6 months and below
Trial Updated:
06/09/2025
Locations: Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: Retinopathy of Prematurity
Register for Updates
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
NCT05711719
Recruiting
Coronary vascular dysfunction is one of the "final common pathways" for the impact of multiple cardiovascular risk factors. The investigators will conduct a randomized, double-blind placebo-controlled study in individuals with the metabolic syndrome and baseline coronary vascular dysfunction to evaluate the impact of vericiguat, a stimulator of soluble guanylyl cyclase, on coronary vascular function using non-invasive cardiac magnetic resonance imaging.
Gender:
ALL
Ages:
Between 35 years and 85 years
Trial Updated:
06/09/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Metabolic Syndrome, Coronary Microvascular Dysfunction
Register for Updates
Developmental Impacts of Microplastics Exposure in Early Life
NCT06107933
Recruiting
The goal of this observational study is to characterize and evaluate micro- and nano-plastic (MNP) exposures among mothers and infants in mother-infant dyads 1 or 3 months postpartum living in Baltimore, Maryland. The main questions it aims to answer are: * What MNPs are present in breastmilk and maternal blood samples and in their infants stool sample? * Are there associations between amount of maternal MNPs in breast milk and mass of MNP particles in infant stool? * Which environmental and li... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: East Baltimore Pediatric Inpatient and Outpatient Clinical Research Unit, Baltimore, Maryland
Conditions: Infant Development, Breast Feeding, Environmental Exposure
Register for Updates
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06380517
Recruiting
In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
06/09/2025
Locations: Greater Baltimore Medical Center, Baltimore, Maryland +1 locations
Conditions: Amblyopia
Register for Updates
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
NCT06524882
Recruiting
Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logM... Read More
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
06/09/2025
Locations: Greater Baltimore Medical Center, Baltimore, Maryland +1 locations
Conditions: Amblyopia
Register for Updates
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
NCT06840496
Recruiting
Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
Gender:
FEMALE
Ages:
Between 5 years and 20 years
Trial Updated:
06/09/2025
Locations: Maryland Locations Biomed Testing Facility #BIO-9-21205, Baltimore, Maryland
Conditions: Rett Syndrome
Register for Updates
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
NCT06170970
Recruiting
Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically for MS patients with concomitant excessive daytime sleepiness. This study uses a randomized, double-blind, placebo-controlled crossover design. Participants will undergo a 10-day lead-in with he medicati... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/06/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Multiple Sclerosis, Multiple Sclerosis Fatigue
Register for Updates